Fox Run Management L.L.C. Makes New $788,000 Investment in Denali Therapeutics Inc. (NASDAQ:DNLI)

Fox Run Management L.L.C. acquired a new position in shares of Denali Therapeutics Inc. (NASDAQ:DNLI) during the fourth quarter, HoldingsChannel.com reports. The institutional investor acquired 38,668 shares of the company’s stock, valued at approximately $788,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Victory Capital Management Inc. increased its stake in Denali Therapeutics by 163.7% during the 3rd quarter. Victory Capital Management Inc. now owns 39,900 shares of the company’s stock worth $1,162,000 after acquiring an additional 24,767 shares during the period. FMR LLC increased its stake in shares of Denali Therapeutics by 3,234.3% in the 3rd quarter. FMR LLC now owns 7,831,378 shares of the company’s stock valued at $228,128,000 after purchasing an additional 7,596,508 shares during the last quarter. Algert Global LLC increased its stake in shares of Denali Therapeutics by 82.4% in the 3rd quarter. Algert Global LLC now owns 48,630 shares of the company’s stock valued at $1,417,000 after purchasing an additional 21,975 shares during the last quarter. Proficio Capital Partners LLC bought a new position in shares of Denali Therapeutics in the 4th quarter valued at $514,000. Finally, JPMorgan Chase & Co. increased its stake in shares of Denali Therapeutics by 6.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 235,386 shares of the company’s stock valued at $6,857,000 after purchasing an additional 14,324 shares during the last quarter. Institutional investors own 92.92% of the company’s stock.

Insider Activity

In other news, Director Vicki L. Sato sold 3,080 shares of the business’s stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $20.91, for a total value of $64,402.80. Following the transaction, the director now directly owns 107,976 shares of the company’s stock, valued at $2,257,778.16. The trade was a 2.77 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Ryan J. Watts sold 29,266 shares of the business’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $20.22, for a total value of $591,758.52. Following the completion of the transaction, the chief executive officer now directly owns 260,721 shares in the company, valued at $5,271,778.62. This represents a 10.09 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 47,940 shares of company stock valued at $973,442 in the last ninety days. 7.90% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. William Blair reiterated an “outperform” rating on shares of Denali Therapeutics in a research note on Friday, February 28th. Deutsche Bank Aktiengesellschaft assumed coverage on Denali Therapeutics in a research note on Tuesday, February 11th. They issued a “buy” rating and a $31.00 price target on the stock. HC Wainwright lifted their price target on Denali Therapeutics from $80.00 to $87.00 and gave the company a “buy” rating in a research note on Friday, February 28th. The Goldman Sachs Group cut their price objective on Denali Therapeutics from $45.00 to $40.00 and set a “buy” rating on the stock in a report on Tuesday, January 28th. Finally, Oppenheimer cut their price objective on Denali Therapeutics from $50.00 to $42.00 and set an “outperform” rating on the stock in a report on Monday, March 3rd. Two analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $37.20.

Denali Therapeutics Trading Down 1.2 %

Shares of DNLI opened at $14.43 on Monday. The company has a market capitalization of $2.10 billion, a PE ratio of -5.23 and a beta of 1.46. Denali Therapeutics Inc. has a 12 month low of $14.01 and a 12 month high of $33.33. The stock’s 50-day moving average price is $19.68 and its two-hundred day moving average price is $23.61.

Denali Therapeutics (NASDAQ:DNLI) last announced its earnings results on Thursday, February 27th. The company reported ($0.67) EPS for the quarter, topping the consensus estimate of ($0.75) by $0.08. Equities research analysts predict that Denali Therapeutics Inc. will post -2.71 EPS for the current fiscal year.

Denali Therapeutics Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.